← Leaderboards
James Freeman
University Of Texas Hlth Sci Ctr San Ant
$3,799,466
Attributed
$3,799,466
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $334.1K · FY2005–18$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,799,466 · 3
VA$0 · 2
By mechanism
R01$3,197,548 · 1
R21$321,200 · 1
R56$280,718 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Gregory R Mundy$7,763,862
- Ian M Thompson$52,633,085
- Anne-Marie Langevin$14,142,348
- Theresa A Guise$8,674,181
- S Gail Eckhardt$7,082,740
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPropertyPreventSignal TransductionMediatingCellsChemotherapyMalignant Neoplasm Of PancreasTumorPlayTumor ProgressionOutcome ForecastReportingPancreatic Ductal AdenocarcinomaBaseResistanceLinkAdenocarcinoma CellNeoplastic CellLeadNeoplasm MetastasisKnock-DownCancer EtiologyPathway Interactions
Grant awards (22)
Role of CD44 in adaptive plasticity of pancreatic cancer$0
I01 · FY2018 · VA · contact PI
Role of CD44 in adaptive plasticity of pancreatic cancer$0
I01 · FY2017 · VA · contact PI
Role of CD44 in adaptive plasticity of pancreatic cancer$0
I01 · FY2016 · VA · contact PI
Role of CD44 in adaptive plasticity of pancreatic cancer$0
I01 · FY2015 · VA · contact PI
Role of TGFBeta alterations in pancreatic cancer$316,496
R01 · FY2014 · CA · contact PI
Role of Ron kinase in pancreatic cancer$0
I01 · FY2014 · VA · contact PI
Role of TGFBeta alterations in pancreatic cancer$306,707
R01 · FY2013 · CA · contact PI
Role of Ron kinase in pancreatic cancer$0
I01 · FY2013 · VA · contact PI
Role of TGFBeta alterations in pancreatic cancer$325,738
R01 · FY2012 · CA · contact PI
Role of Ron kinase in pancreatic cancer$0
I01 · FY2012 · VA · contact PI
Role of TGFBeta alterations in pancreatic cancer$324,101
R01 · FY2011 · CA · contact PI
Role of Ron kinase in pancreatic cancer$0
I01 · FY2011 · VA · contact PI
Role of TGFBeta alterations in pancreatic cancer$334,125
R01 · FY2010 · CA · contact PI
Role of TGF-beta alterations in pancreatic cancer$280,718
R56 · FY2009 · CA · contact PI
Role of ErbB/Stat3 in the establishment and progression of pancreatic cancer$204,400
R21 · FY2008 · CA · contact PI
Role of ErbB/Stat3 in the establishment and progression of pancreatic cancer$116,800
R21 · FY2007 · CA · contact PI
Role of TGFB Receptor Alterations in Pancreatic Cancer$268,030
R01 · FY2006 · CA · contact PI
Role of TGFB Receptor Alterations in Pancreatic Cancer$274,480
R01 · FY2005 · CA
Role of TGFB Receptor Alterations in Pancreatic Cancer$274,480
R01 · FY2004 · CA
Role of TGFB Receptor Alterations in Pancreatic Cancer$274,480
R01 · FY2003 · CA
Role of TGFB Receptor Alterations in Pancreatic Cancer$274,480
R01 · FY2002 · CA
TGF-B RECEPTOR ALTERATIONS AND PANCREAS CANCER$224,431
R01 · FY2000 · CA